开源AI模型预测肺腺癌EGFR突变的 ancestrY相关性能差异
该队列研究评估两种开源AI病理模型在肺腺癌中预测EGFR突变状态的性能与泛化性,纳入DFCI队列1759例和TNM-I队列339例。较高性能模型在DFCI的AUC为0.83,TNM-I为0.81;在DFCI中按祖源分层,欧洲裔AUC 0.84、非洲裔0.85、亚洲裔0.68。胸膜标本性能(AUC 0.66)低于肺标本(AUC 0.86)。
要点
- 开源AI病理模型预测EGFR突变总体AUC 0.81-0.83,但亚洲裔人群AUC降至0.68。
- 胸膜标本预测性能(AUC 0.66)显著低于肺标本(AUC 0.86)。
- AI分诊可潜在减少57%快速EGFR检测,敏感度0.84、特异度0.99。
核心结论
- AI病理工具可作为肺癌EGFR预测的初步辅助手段,但祖源相关性能差异需谨慎解读。
研究设计与样本
- DFCI队列通过胚系基因型数据推断遗传祖源。
主要发现
- DFCI队列中EGFR突变检出432例(25%),较高性能模型AUC 0.83(95%CI 0.81-0.85),另一模型AUC 0.68(95%CI 0.65-0.70)。
- TNM-I队列中EGFR突变检出50例(15%),两模型AUC分别为0.81(95%CI 0.74-0.88)和0.75(95%CI 0.68-0.83)。
- DFCI队列祖源分层:较高性能模型在欧洲裔AUC 0.84(95%CI 0.81-0.86)、非洲裔AUC 0.85(95%CI 0.72-0.94)、亚洲裔AUC 0.68(95%CI 0.55-0.78)。
- 样本类型分析:胸膜标本AUC 0.66(95%CI 0.56-0.76),肺标本AUC 0.86(95%CI 0.83-0.88)。
- AI引导分诊分析显示潜在减少57%快速EGFR检测,同时保持敏感度0.84和特异度0.99。
临床怎么用
- AI模型可用于肺腺癌EGFR突变的初步分诊,但需注意亚洲裔人群和胸膜标本中性能下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Artificial intelligence (AI) models are emerging as rapid, low-cost tools for predicting targetable genomic alterations directly from routine pathology slides. Although these approaches could accelerate treatment decisions in lung cancer, little is known about whether their performance is consistent across diverse patient populations and tissue contexts. OBJECTIVE: To evaluate the performance and generalizability of 2 open-source AI pathology models for predicting EGFR mutation status in lung adenocarcinoma (LUAD) across independent cohorts and ancestral subgroups. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included patients with LUAD from 2 cohorts: Dana-Farber Cancer Institute (DFCI) from June 2013 to November 2023, and a European-based trial (TNM-I) from August 2016 to February 2022. All patients had paired next-generation sequencing data and hematoxylin-eosin-stained whole-slide images. In the DFCI cohort, genetic ancestry was inferred using germline genotype data. Data analyses were performed from July 2025 to September 2025. MAIN OUTCOMES: The primary outcome was model performance for predicting EGFR mutation status, measured as the area under the receiver operating characteristic curve (AUC), evaluated overall and across ancestry subgroups and sample types. RESULTS: Overall, 2098 patients with LUAD were included (mean [SD] age, 66.6 [10.3] years; 1315 female individuals [63%] and 783 male individuals [37%]). In the DFCI cohort (n = 1759; 54 African, 101 American, 95 Asian, 1465 European), EGFR mutations were detected in 432 patients (25%). One AI-pathology model achieved an AUC of 0.83 (95% CI, 0.81-0.85) compared with 0.68 (95% CI, 0.65-0.70) for the other model. In the TNM-I cohort (n = 339), EGFR mutations were detected in 50 patients (15%), with AUCs of 0.81 (95% CI, 0.74-0.88) and 0.75 (95% CI, 0.68-0.83), respectively. In ancestry-stratified analyses of the DFCI cohort, AUCs for the higher-performing model were 0.84 (95% CI, 0.81-0.86) in patients of European ancestry, 0.85 (95% CI, 0.72-0.94) in African ancestry, and 0.68 (95% CI, 0.55-0.78) in Asian ancestry. In sample type analyses, performance declined in pleural (AUC, 0.66; 95% CI, 0.56-0.76) compared with lung specimens (AUC, 0.86; 95% CI, 0.83-0.88). AI-guided triage analyses showed a potential 57% reduction in rapid EGFR testing, while maintaining sensitivity of 0.84 and specificity of 0.99. CONCLUSIONS: This cohort study found that AI-based pathology tools may serve as preliminary adjuncts for EGFR prediction in lung cancer, though performance differences by ancestry warrant careful interpretation.
引用
- Rakaee M, Nassar AH, Tafavvoghi M, et al. Ancestry-Associated Performance Variability of Open-Source AI Models for EGFR Prediction in Lung Cancer. JAMA Oncol. 2026. PMID: 41678173. doi:10.1001/jamaoncol.2025.6430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。